c flox tz veterinary price Performance Analysis-NEWS-Dingzhou Kangquan Pharmaceutical - Professional Veterinary Medicine Manufacturer

Introduction

Ciprofloxacin and Metronidazole, combined and marketed as C Flox TZ, represent a critical therapeutic intervention in veterinary medicine, specifically for combating bacterial infections in animals. This formulation is a broad-spectrum antibiotic, leveraging the synergistic effects of a fluoroquinolone (ciprofloxacin) and an imidazole derivative (metronidazole) to address a wide array of pathogens. Its technical position within the veterinary pharmaceutical supply chain is as a finished dosage form, requiring stringent quality control and adherence to pharmacopoeial standards. Core performance centers around achieving rapid bacterial cell death, hindering bacterial DNA replication (ciprofloxacin), and disrupting anaerobic bacterial metabolism (metronidazole). The increasing prevalence of antibiotic resistance necessitates a thorough understanding of its efficacy, optimal usage protocols, and potential limitations. This guide provides an in-depth technical overview of C Flox TZ, encompassing its material composition, manufacturing processes, performance characteristics, potential failure modes, and relevant industry regulations.

Material Science & Manufacturing

C Flox TZ’s manufacturing begins with the sourcing of high-purity active pharmaceutical ingredients (APIs): Ciprofloxacin Hydrochloride and Metronidazole. Ciprofloxacin Hydrochloride is a synthetic fluoroquinolone antibacterial agent. Its crystalline structure influences solubility and bioavailability. Raw material specifications dictate a minimum purity of 98% as determined by High-Performance Liquid Chromatography (HPLC). Metronidazole, a nitroimidazole antibiotic, exists as a crystalline powder. Its particle size distribution is critical for ensuring uniform dispersion within the final formulation. Excipients, including microcrystalline cellulose, lactose monohydrate, sodium starch glycolate, and magnesium stearate, are utilized for binding, disintegration, and lubrication during tablet compression. The manufacturing process typically involves blending of the APIs and excipients, granulation (wet or dry), tablet compression, and film coating. Critical process parameters (CPPs) include blending time and speed, granulation moisture content, compression force, and coating pan speed. These parameters are meticulously controlled to ensure tablet hardness, friability, disintegration time, and drug release profile meet established specifications. Film coating, often using hypromellose (HPMC) based formulations, provides protection from environmental factors (moisture, light) and aids in swallowability. Raw material compatibility studies are essential to prevent chemical degradation and ensure formulation stability.

Performance & Engineering

The combined antibacterial action of ciprofloxacin and metronidazole provides a synergistic effect, broadening the spectrum of activity against both aerobic and anaerobic bacteria commonly encountered in veterinary infections. Ciprofloxacin's mechanism involves inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, repair, and recombination. Metronidazole functions by entering bacterial cells and undergoing reductive activation, forming cytotoxic products that disrupt DNA structure and inhibit nucleic acid synthesis. Pharmacokinetic studies demonstrate varying absorption rates depending on the animal species and route of administration. Bioavailability is a critical performance parameter, directly impacting therapeutic efficacy. Formulation engineering focuses on maximizing drug dissolution and absorption. Environmental resistance is assessed through stability studies, evaluating degradation rates under various temperature, humidity, and light exposure conditions. Compliance requirements dictated by veterinary regulatory bodies (e.g., FDA-CVM in the US, EMA in Europe) necessitate rigorous validation of manufacturing processes and demonstration of product efficacy and safety through clinical trials. Dosage calculations are based on animal weight and the severity of the infection, requiring precise concentration control in the finished product. Force analysis during tablet compression ensures mechanical integrity and minimizes friability, essential for handling and administration.

Technical Specifications

Parameter	Specification (Ciprofloxacin HCl)	Specification (Metronidazole)	Specification (Combined Formulation)
Assay (HPLC)	98.0% - 102.0%	98.0% - 102.0%	Ciprofloxacin HCl: 50mg/tablet ± 5%; Metronidazole: 250mg/tablet ± 5%
Water Content (Karl Fischer)	≤ 1.0%	≤ 0.5%	≤ 1.5%
Particle Size (D90)	≤ 100 µm	≤ 75 µm	N/A – assessed for API raw materials only
Tablet Hardness	N/A	N/A	88-118 N
Friability	N/A	N/A	≤ 1.0%
Disintegration Time	N/A	N/A	≤ 30 minutes

Failure Mode & Maintenance

Potential failure modes of C Flox TZ include tablet cracking or chipping due to inadequate hardness, leading to dosage variability. This can arise from insufficient binder concentration or excessive compression force. Degradation of the APIs is a significant concern. Ciprofloxacin is susceptible to photolysis (degradation by light), necessitating opaque packaging. Metronidazole can undergo oxidation, particularly in the presence of moisture and elevated temperatures, reducing its potency. Delamination of the film coating can occur due to poor adhesion, compromising tablet protection and aesthetic appeal. Microbial contamination during manufacturing or storage is a critical failure point. Maintenance protocols include strict adherence to Good Manufacturing Practices (GMP), regular equipment calibration and cleaning, comprehensive raw material testing, and controlled storage conditions (temperature, humidity, light). Stability studies should be conducted periodically to monitor API degradation and ensure product shelf life. Visual inspection of tablets for defects (cracks, chips, discoloration) is essential. Any batch failing to meet pre-defined quality control specifications should be rejected and investigated thoroughly.

Industry FAQ

Q: What is the impact of different excipient grades on the dissolution rate of C Flox TZ?

A: Different grades of excipients, particularly microcrystalline cellulose and sodium starch glycolate, directly impact the dissolution rate. Higher grades of cellulose can provide greater binding strength but may hinder drug release. Optimizing the ratio and particle size of these excipients is crucial for achieving rapid and complete drug dissolution, influencing bioavailability and therapeutic efficacy. Dissolution testing, adhering to USP or EP methodologies, is vital for quality control.

Q: How does humidity affect the stability of Metronidazole within the C Flox TZ formulation?

A: Metronidazole is hygroscopic and susceptible to degradation in the presence of moisture. Elevated humidity can accelerate oxidation and reduce potency. Appropriate packaging (e.g., blister packs with desiccant) and controlled storage conditions (low humidity) are essential to maintain stability. Regular monitoring of moisture content using Karl Fischer titration is recommended.

Q: What analytical methods are used to verify the absence of residual solvents from the manufacturing process?

A: Gas Chromatography with Mass Spectrometry (GC-MS) is the primary analytical technique used to detect and quantify residual solvents. The acceptable limits for residual solvents are defined by ICH Q3C guidelines. Validation of the GC-MS method is crucial to ensure accurate and reliable results.

Q: Can C Flox TZ be compounded into alternative dosage forms (e.g., oral suspensions) and what considerations are necessary?

A: While compounding is possible, it introduces significant challenges in maintaining dosage accuracy and sterility. Compounding pharmacies must adhere to USP <795> and <800> guidelines. Compatibility of the APIs with excipients used in the compounded formulation must be verified. Stability of the compounded preparation needs to be assessed and a beyond-use date established.

Q: What are the key regulatory requirements for demonstrating bioequivalence of generic C Flox TZ formulations?

A: Bioequivalence studies, typically conducted according to FDA or EMA guidelines, are required to demonstrate that the generic formulation exhibits comparable bioavailability to the reference listed drug. This involves comparing pharmacokinetic parameters (AUC and Cmax) between the two formulations in a randomized, crossover study. Statistical analysis, using appropriate confidence intervals, is used to determine bioequivalence.

Conclusion

C Flox TZ represents a potent combination antibiotic essential for veterinary practice. Its efficacy is predicated on meticulous control of both material properties and manufacturing processes. Understanding the chemical vulnerabilities of ciprofloxacin and metronidazole, coupled with robust quality control measures, is paramount to ensuring product stability and therapeutic effectiveness. Continued monitoring of antibiotic resistance patterns and adherence to evolving regulatory standards are critical for maintaining the clinical utility of this formulation.

Future development efforts should focus on novel formulation strategies – such as nano-delivery systems – to improve bioavailability, reduce dosage requirements, and mitigate the development of antibiotic resistance. Further research into the pharmacokinetic and pharmacodynamic interactions between ciprofloxacin and metronidazole in various animal species is also warranted to optimize dosage regimens and enhance treatment outcomes.

Apr . 01, 2024 17:55 Back to list

c flox tz veterinary price Performance Analysis